Steven Laken Named One of the World's Top Young Innovators by Technology Review, MIT's Magazine of Innovation.Business/Technology Editors and Health/Medical Writers MAYNARD, Mass.--(BW HealthWire)--May 23, 2002 Laken to be honored at exclusive event where international leaders connect with 100 top innovators under age 35 EXACT Sciences Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :EXAS) today announced that Steven Laken, PhD, Director of Business Development, has been chosen as one of the world's 100 Top Young Innovators by Technology Review, MIT's award-winning Magazine of Innovation. The TR100 consists of 100 individuals under the age of 35 whose innovative work in business and technology have a profound impact on today's world. Nominees are recognized for their contribution in transforming the nature of technology in industries such as biotechnology, computing, energy, medicine, manufacturing, nanotechnology, telecommunications and transportation. "Steve's knowledge and expertise have been invaluable to our Company as we develop our genomics-based technologies to detect cancer," stated Don Hardison, EXACT Sciences' President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "Steve's early work in Bert Vogelstein's laboratory at Johns Hopkins University Johns Hopkins University, mainly at Baltimore, Md. Johns Hopkins in 1867 had a group of his associates incorporated as the trustees of a university and a hospital, endowing each with $3.5 million. Daniel C. was the perfect scientific preparation for the work we are doing at EXACT Sciences. What is unique about Steve, however, is his interest and ability in using that knowledge outside of the laboratory in a business setting. We are delighted that he is a member of the EXACT Sciences team as we develop and commercialize technologies to fulfill our mission of eradicating the mortality from cancer through early detection." Laken has worked extensively on PreGen(TM), EXACT Sciences' non-invasive, genomics-based technologies for the early detection of cancer. The company's first target is colorectal cancer colorectal cancer Malignant tumour of the large intestine (colon) or rectum. Risk factors include age (after age 50), family history of colorectal cancer, chronic inflammatory bowel diseases, benign polyps, physical inactivity, and a diet high in fat. , the deadliest cancer among non-smoking men and women in the U.S. By removing some of the common barriers associated with current screening methods, EXACT Sciences believes that its technologies will help to increase colorectal cancer screening rates and lower the mortality associated with colorectal cancer. Laken will be honored during a conference and awards ceremony at the Massachusetts Institute of Technology Massachusetts Institute of Technology, at Cambridge; coeducational; chartered 1861, opened 1865 in Boston, moved 1916. It has long been recognized as an outstanding technological institute and its Sloan School of Management has notable programs in business, on Thurs., May 23. The event, themed "The Innovation Economy: How Technology is Transforming Existing Businesses and Creating New Ones," includes a full day of conference sessions and panel discussions followed by an evening awards ceremony. Hosted by Technology Review's Editor-in-Chief John Benditt and CNBC's Consuelo Mack, conference speakers include international leaders such as Kenneth Starr
Kenneth Winston Starr (born July 21, 1946) is an American lawyer and former judge who was appointed to the Office of the Independent Counsel to investigate the death of the , Esq.; Clayton Christensen, Harvard Business School Harvard Business School, officially named the Harvard Business School: George F. Baker Foundation, and also known as HBS, is one of the graduate schools of Harvard University. professor and author of The Innovators Dilemma; Nadine Strossen Nadine Strossen (born August 18, 1950) is the current president of the American Civil Liberties Union. She is the first woman and the youngest person to ever lead the ACLU. A professor at New York Law School, Professor Strossen also sits on the Council on Foreign Relations. , president of the ACLU ACLU: see American Civil Liberties Union. ; Rodney Brooks, Director of the Artificial Intelligence Laboratory and Co-director of Project Oxygen, MIT MIT - Massachusetts Institute of Technology ; Richard Rashid, Senior Vice President, Microsoft Research; and David Tennenhouse, Vice President and Corporate Technology Group Director, Intel Corporation. TR100's unparalleled panel of judges Panel of Judges is an indie pop band from Melbourne, Australia. Members
- Dr. David Baltimore, President, California Institute of Technology - Alfred Berkeley III, Vice Chairman, NASDAQ - Richard Demillo, Vice President and Chief Technology Officer, Hewlett-Packard - Dr. Philippe Janson, Vice President, IBM Academy of Technology - Dr. Robert M. Metcalfe, Venture Partner, Polaris Venture Partners - Dr. Cherry A. Murray, Senior Vice President of Physical Science Research, Bell Labs/Lucent Technologies - Nicholas Negroponte, Director, MIT Media Laboratory - Dr. Judith Rodin, President, University of Pennsylvania About Technology Review Inc. Technology Review, MIT's magazine of Innovation, is the world's oldest technology magazine. The magazine, as well as its signature events and Internet businesses, delivers essential information on emerging technologies on the verge On the Verge (or The Geography of Yearning) is a play written by Eric Overmyer. It makes extensive use of esoteric language and pop culture references from the late nineteenth century to 1955. of commercialization. Since 1998, Technology Review's paid circulation has more than tripled, from 92,000 to 310,000 (as of January 2002). Several hundred thousand current MIT alumni, faculty and students, senior technology thinkers and influencers - venture capitalists, chief scientists, researchers, senior corporate executives, investors, and innovators throughout the world -- constitute the Technology Review community. About EXACT Sciences Corporation EXACT Sciences Corporation is an applied genomics applied genomics Molecular genetics Molecular medicine The use of genetic information to diagnose, prognosticate and manage disease, based on the techniques of PCR, real time-PCR, DNA sequencing, and gene rearrangement studies for leukemia and lymphoma. company that has developed proprietary technologies that may be used for the early detection of several common cancers. EXACT Sciences has selected colorectal cancer as the first application of its technologies. Colorectal cancer is the most deadly cancer among non-smokers, and is curable cur·a·ble adj. Capable of being cured or healed. if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than 20 years, the rate of early detection of colorectal cancer remains low. EXACT Sciences believes its genomics-based technologies will enable early detection of colorectal cancer so that more people can be effectively treated. Founded in 1995, EXACT Sciences is based in Maynard, Mass. Detailed information on EXACT Sciences can be found on the World Wide Web at www.exactsciences.com. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are subject to a variety of risks and uncertainties, many of which are beyond EXACT Sciences' control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. EXACT Sciences undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by EXACT Sciences, see the disclosure contained in EXACT Sciences' public filings with the Securities and Exchange Commission including, without limitation, its Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2001. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion